New hope for mastocytosis patients: expanded access to bezuclastinib

NCT ID NCT06915766

AVAILABLE Disease control Sponsor: Cogent Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This program provides the investigational drug bezuclastinib to adults with systemic mastocytosis who have failed or cannot tolerate standard treatments. Participants must be at least 18 years old and able to swallow tablets. The goal is to offer a potential treatment option when no satisfactory alternatives exist.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bezuclastinib (also known as CGT9486)
What this could lead to: If this drug works, it could offer a new treatment option for patients with systemic mastocytosis who have run out of standard therapies.
What could go wrong: This is an expanded access program, not a formal trial, so data on effectiveness and safety is still limited. The drug may not work for everyone and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive systemic mastocytosis indolent systemic mastocytosis isolated bone marrow mastocytosis mast cell leukemia Mastocytosis, Systemic Smouldering systemic mastocytosis systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC MASTOCYTOSES, AGGRESSIVE SYSTEMIC MASTOCYTOSES, INDOLENT

Contacts and locations

Show contact details

Locations

AIR Care
AVAILABLE

Dallas, Texas, 75231, United States
AllerVie Health
AVAILABLE

Glenn Dale, Maryland, 20769, United States
Allergy Associates of Utah
AVAILABLE

Sandy City, Utah, 84093, United States
Boston Specialists
AVAILABLE

Boston, Massachusetts, 02111, United States

Contact Email: •••••@•••••
Dana Farber Cancer Institute
AVAILABLE

Boston, Massachusetts, 02215, United States
Dartmouth-Hitchcock Medical Center
AVAILABLE

Lebanon, New Hampshire, 03756, United States
Duke Blood Cancer Center
AVAILABLE

Durham, North Carolina, 27705, United States
Indiana University Health
AVAILABLE

Indianapolis, Indiana, 46202, United States
Mayo Clinic
AVAILABLE

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
AVAILABLE

New York, New York, 10065, United States
Michigan Medicine- University of Michigan
AVAILABLE

Ann Arbor, Michigan, 48109, United States
Northern Light Eastern Maine Medical Center
AVAILABLE

Bangor, Maine, 04401, United States
Northwest Medical Specialties
AVAILABLE

Tacoma, Washington, 98405, United States

Contact Email: •••••@•••••
Orso Health/Modena Asthma Allergy
AVAILABLE

La Jolla, California, 92037, United States
Scripps Green Hospital
AVAILABLE

La Jolla, California, 92037, United States
Sneeze Wheeze & Itch Associates LLC Clinical Research Center
AVAILABLE

Normal, Illinois, 61761, United States
Texas Children's Hospital
AVAILABLE

Houston, Texas, 77030, United States
The Ohio State University Wexner Medical Center
AVAILABLE

Columbus, Ohio, 43210, United States
The University of Texas, MD Anderson Cancer Center
AVAILABLE

Houston, Texas, 77030, United States
UCLA Ronald Reagan Medical Center
AVAILABLE

Los Angeles, California, 90095, United States
University of Utah - Huntsman Cancer Institute
AVAILABLE

Salt Lake City, Utah, 84112, United States
Walter Reed
AVAILABLE

Bethesda, Maryland, 20889, United States
Washington University School of Medicine in St. Louis
AVAILABLE

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.